MX2017008818A - Metodos para tratar enfermedades de la retina. - Google Patents

Metodos para tratar enfermedades de la retina.

Info

Publication number
MX2017008818A
MX2017008818A MX2017008818A MX2017008818A MX2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A
Authority
MX
Mexico
Prior art keywords
subject
cells
treating
methods
retinal diseases
Prior art date
Application number
MX2017008818A
Other languages
English (en)
Inventor
Banin Eyal
Eithan Reubinoff Benjamin
BOHANA-KASHTAN Osnat
Netzer Nir
Sherard Irving Charles
Original Assignee
Cell Cure Neurosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017008818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Cure Neurosciences Ltd filed Critical Cell Cure Neurosciences Ltd
Publication of MX2017008818A publication Critical patent/MX2017008818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe un método para tratar un sujeto con degeneración macular relacionada con la edad forma seca (AMD). El método comprende administrar en la subretina del sujeto una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende células RPE humanas, en donde al menos 95% de las células de la misma coexpresan proteína premelanosoma (PMEL17) y proteína de unión de retinaldehído celular (CRALBP), en donde la resistencia eléctrica transepitelial de las células es mayor que 100 ohms al sujeto, tratando por ello al sujeto. (ver Dibujo).
MX2017008818A 2014-12-30 2015-04-30 Metodos para tratar enfermedades de la retina. MX2017008818A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US201562116980P 2015-02-17 2015-02-17
US201562116972P 2015-02-17 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Publications (1)

Publication Number Publication Date
MX2017008818A true MX2017008818A (es) 2018-03-14

Family

ID=56284392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008818A MX2017008818A (es) 2014-12-30 2015-04-30 Metodos para tratar enfermedades de la retina.

Country Status (18)

Country Link
US (2) US20180008458A1 (es)
EP (1) EP3240612B1 (es)
JP (4) JP2018501281A (es)
KR (2) KR102514912B1 (es)
CN (3) CN114469998A (es)
AU (3) AU2015373111B2 (es)
BR (1) BR112017014332A2 (es)
CA (2) CA3175175A1 (es)
DK (1) DK3240612T3 (es)
EA (1) EA201791518A1 (es)
ES (1) ES2843626T3 (es)
HK (1) HK1246179A1 (es)
IL (1) IL253244B2 (es)
MX (1) MX2017008818A (es)
PH (1) PH12017501217A1 (es)
SG (1) SG11201705378RA (es)
WO (1) WO2016108219A1 (es)
ZA (1) ZA201704359B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073730B1 (ko) 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
MX2017008818A (es) 2014-12-30 2018-03-14 Cell Cure Neurosciences Ltd Metodos para tratar enfermedades de la retina.
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
CA2972580A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
ES2865024T3 (es) 2015-07-29 2021-10-14 Hadasit Med Res Service Producción a gran escala de células de epitelio pigmentario retiniano
AU2016303631B2 (en) 2015-08-05 2022-07-28 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
EP3595687A1 (en) * 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
AU2018308976A1 (en) 2017-07-31 2020-02-20 Biotime, Inc. Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury
EP3731789A4 (en) * 2017-12-29 2021-09-08 Cell Cure Neurosciences Ltd. RETINAL PIGMENTARY EPITHELIUM CELL COMPOSITIONS
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
US20220259558A1 (en) * 2019-05-15 2022-08-18 Novo Nordisk A/S Methods for obtaining eye field progenitor cells from human pluripotent stem cells
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
IL301042A (en) * 2020-09-03 2023-05-01 Curebiotec Gmbh Pigment epithelium-derived factor (PEDF) for use in the treatment of macular degeneration or neovascularization
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115212233B (zh) * 2022-08-26 2024-05-28 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP3640326A1 (en) 2007-04-18 2020-04-22 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
CA3177952A1 (en) * 2007-10-12 2009-04-23 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
KR102073730B1 (ko) * 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
RS59050B1 (sr) * 2011-11-14 2019-08-30 Astellas Inst For Regenerative Medicine Farmaceutski preparati humanih rpe ćelija i njihova upotreba
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
KR101483988B1 (ko) * 2012-04-09 2015-01-28 연세대학교 산학협력단 망막하 주사 또는 추출용 중공형 마이크로니들 및 망막하 주사기
DK2951290T3 (en) 2013-02-01 2018-01-22 Us Health PROCEDURE FOR PREPARING RETINAL PIGMENTAL EPIT (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS)
JP2017504311A (ja) * 2013-12-11 2017-02-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 網膜色素上皮細胞を生成する方法
MX2017008818A (es) 2014-12-30 2018-03-14 Cell Cure Neurosciences Ltd Metodos para tratar enfermedades de la retina.
CA2972580A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Also Published As

Publication number Publication date
PH12017501217A1 (en) 2018-01-29
CA3175175A1 (en) 2016-07-07
AU2015373111A1 (en) 2017-07-13
EP3240612A1 (en) 2017-11-08
US20180008458A1 (en) 2018-01-11
KR20220020422A (ko) 2022-02-18
KR20170120583A (ko) 2017-10-31
IL253244B2 (en) 2023-09-01
EP3240612B1 (en) 2020-12-23
JP2020143137A (ja) 2020-09-10
AU2023255009A1 (en) 2023-11-16
ES2843626T3 (es) 2021-07-19
CN114469998A (zh) 2022-05-13
BR112017014332A2 (pt) 2018-01-02
US20230028133A1 (en) 2023-01-26
CN114533761A (zh) 2022-05-27
AU2015373111B2 (en) 2021-06-24
EA201791518A1 (ru) 2017-10-31
CA2972700A1 (en) 2016-07-07
HK1246179A1 (zh) 2018-09-07
ZA201704359B (en) 2018-08-29
KR102514912B1 (ko) 2023-03-27
CN107427534A (zh) 2017-12-01
EP3240612A4 (en) 2018-06-13
JP2024023611A (ja) 2024-02-21
SG11201705378RA (en) 2017-08-30
AU2021229196A1 (en) 2021-10-07
WO2016108219A1 (en) 2016-07-07
DK3240612T3 (da) 2021-01-18
JP2018501281A (ja) 2018-01-18
IL253244A0 (en) 2017-08-31
JP2022125160A (ja) 2022-08-26
IL253244B1 (en) 2023-05-01
KR102359257B1 (ko) 2022-02-07

Similar Documents

Publication Publication Date Title
PH12017501217A1 (en) Methods of treating retinal diseases
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2019010907A (es) Agonistas del receptor x farnesoide, y usos de los mismos.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
MX2016006688A (es) Inhibidores tetraciclicos de autotaxina.
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
PH12018501002A1 (en) Pheromone composition to stimulate reproduction in female suids and method of use
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EP3416500A4 (en) DRUG COMBINATIONS AND METHODS FOR STIMULATING EMBRYO-LIKE REGENERATION TO TREAT DIABETES AND OTHER DISEASES
EP3634438A4 (en) COMPOSITIONS FOR THE TREATMENT OF RETINAL DISEASES AND THEIR PRODUCTION AND USE METHODS
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use